This is why Medicare needs to adopt a quality adjusted life year test for medical reimbursement, like most countries with socialized healthcare.

The FDA should not be taking costs and pricing into account when approving new drugs.

Similarly, the taxpayers should not be on the hook for speculative new treatments.